QOL and Sarcopenia in Patients With Ascites
Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of lif
| Condition(s) | Ascites Hepatic, Ascites, Malignant |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of life survey instruments specific to benign and malignant etiologies. Sarcopenia is a condition that is prevalent in cancer and cirrhosis. Current data is retrospective and associative, evaluating heterogeneous patient populations at different stages within the timeline of refractory ascites. The other primary objective of this study is to study sarcopenia in a prospective fashion and to understand its kinetics once a patient develops refractory ascites. Prospectively-obtained me |
| Who can participate | Inclusion Criteria: 1. Age \>/=18 2. Eastern Cooperative Oncology Group (ECOG) performance score \< 3 3. Refractory ascites due to cirrhosis or malignancy, requiring more than 1 therapeutic paracentesis in a 6 week period within 3 months of enrollment. 4. Capable of giving informed consent Exclusion Criteria: 1. Life expectancy less than 3 months 2. Unable to participate in neuropsychological tests/questionnaires 3. Pregnant or nursing women. . |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
| Locations | Philadelphia, Pennsylvania, United States |
| Start date | 2023-05-23 |
| NCT ID | NCT05726747 |
| Official listing | https://clinicaltrials.gov/study/NCT05726747 |